<p>Intravesical photodynamic therapy (PDT) emerges as a promising modality for bladder cancer treatment, yet its efficacy is often curtailed by weak muco-adhesion, poor muco-penetration, low tumor-targeting and intra-tumoral oxygen scarcity. In this work, we introduce a drug delivery system leveraging cerium oxide (CeO<sub>2</sub>) nanozymes as the core, polyarginine peptides R11 as the tumor-targeting ligands, and indocyanine green (ICG) as the photosensitizers, with the latter two components assembled on the particle surface. Intravesical ICG@R11-CeO<sub>2</sub> nanoparticles displayed enhanced mucoadhesive, mucus-penetrating and tumor-targeting properties, and effectively mitigated the hypoxia threat in the tumor microenvironment to improve the PDT sensitivity. Remarkably, the intravesical PDT via ICG@R11-CeO<sub>2</sub> nanoparticles achieved complete tumor inhibition in orthotopic bladder cancer models, offering strong evidence on its clinical translational potential.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Intravesical delivery of mucoadhesive and tumor-selective-penetrating nanozymes for enhancing the PDT of bladder cancer

  • Yang Liu,
  • Wentao Xu,
  • Xiaowen Qin,
  • Jiajia Zheng,
  • Bin Zheng,
  • Li Sun,
  • Wenyan Zuo,
  • Dingyi Liu,
  • Zhenghong Liu,
  • Yixuan Mou,
  • Heng Wang,
  • Qi Zhang,
  • Jun Chen,
  • Pu Zhang,
  • Dahong Zhang

摘要

Intravesical photodynamic therapy (PDT) emerges as a promising modality for bladder cancer treatment, yet its efficacy is often curtailed by weak muco-adhesion, poor muco-penetration, low tumor-targeting and intra-tumoral oxygen scarcity. In this work, we introduce a drug delivery system leveraging cerium oxide (CeO2) nanozymes as the core, polyarginine peptides R11 as the tumor-targeting ligands, and indocyanine green (ICG) as the photosensitizers, with the latter two components assembled on the particle surface. Intravesical ICG@R11-CeO2 nanoparticles displayed enhanced mucoadhesive, mucus-penetrating and tumor-targeting properties, and effectively mitigated the hypoxia threat in the tumor microenvironment to improve the PDT sensitivity. Remarkably, the intravesical PDT via ICG@R11-CeO2 nanoparticles achieved complete tumor inhibition in orthotopic bladder cancer models, offering strong evidence on its clinical translational potential.